GDF-11

Summary

Elevian is working on therapies focused on GDF-11, a blood factor that has been reported to reverse age-related hypertrophy, age-related dysfunction of skeletal muscle, and similar disorders while improving cerebral blood flow and improving metabolism.

The blood of younger animals contains different proportions of blood factors than the blood of older animals, and giving young blood to aged animals, such as through parabiosis, has been shown to positively affect their health. GDF-11 is one of these factors, and Elevian is developing therapies that combine it with other blood factors in order to treat age-related diseases.

Its research is currently in the early stages, including preclinical treatments for coronary artery disease, type 2 diabetes, and Alzheimer’s disease. It is also researching ways to treat sarcopenia.

To further its research and product development, Elevian has purchased relevant patents from Harvard University.

References

Conboy, I. M., Conboy, M. J., Wagers, A. J., Girma, E. R., Weissman, I. L., & Rando, T. A. (2005). Rejuvenation of aged progenitor cells by exposure to a young systemic environment. Nature433(7027), 760.

Loffredo, F. S., Steinhauser, M. L., Jay, S. M., Gannon, J., Pancoast, J. R., Yalamanchi, P., … & Miller, C. M. (2013). Growth differentiation factor 11 is a circulating factor that reverses age-related cardiac hypertrophy. Cell, 153(4), 828-839.

Sinha, M., Jang, Y. C., Oh, J., Khong, D., Wu, E. Y., Manohar, R., … & Hirshman, M. F. (2014). Restoring systemic GDF11 levels reverses age-related dysfunction in mouse skeletal muscle. Science, 344(6184), 649-652.

Katsimpardi, L., Litterman, N. K., Schein, P. A., Miller, C. M., Loffredo, F. S., Wojtkiewicz, G. R., … & Rubin, L. L. (2014). Vascular and neurogenic rejuvenation of the aging mouse brain by young systemic factors. Science, 344(6184), 630-634.

Walker, R. G., Poggioli, T., Katsimpardi, L., Buchanan, S. M., Oh, J., Wattrus, S., … & Thompson, T. B. (2016). Biochemistry and biology of GDF11 and myostatin: similarities, differences, and questions for future investigation. Circulation research, 118(7), 1125-1142.

Walker, R. G., Czepnik, M., Goebel, E. J., McCoy, J. C., Vujic, A., Cho, M., … & Bernard, D. J. (2017). Structural basis for potency differences between GDF8 and GDF11. BMC biology, 15(1), 19.

Walker, R. G., McCoy, J. C., Czepnik, M., Mills, M. J., Hagg, A., Walton, K. L., … & Harrison, C. A. (2018). Molecular characterization of latent GDF8 reveals mechanisms of activation. Proceedings of the National Academy of Sciences, 201714622.

Website: Elevian

Articles:

Elevian Launches to Join Numerous Companies Focused on Longevity and Aging

Elevian is developing medicine to prevent age-related diseases